RMC No. 62-2020 lists VAT-exempt prescription drugs for diabetes, high cholesterol, and hypertension effective January 27, 2020.
Pharmacies, hospitals, clinics, importers, distributors, and VAT-registered sellers must treat only the listed prescription drugs and medicines for diabetes, high cholesterol, and hypertension as VAT-exempt beginning January 27, 2020. The key business consequence of RMC No. 62-2020 is that VAT exemption depends not merely on the illness category, but on the specific generic name, dosage strength, and dosage form appearing in the published list provided by the Food and Drug Administration of the Department of Health.
What RMC No. 62-2020 changed
RMC No. 62-2020 published the list of prescription drugs and medicines for diabetes, high cholesterol, and hypertension that are exempt from value-added tax beginning January 27, 2020. For businesses selling, purchasing, importing, prescribing, or reimbursing medicines, this matters because the VAT treatment is tied to the exact medicine entry. A product is not automatically VAT-exempt simply because it is generally used for diabetes, high cholesterol, or hypertension. The safer compliance position is to match the product against the published list by generic name, dosage strength, and dosage form.
The list covers major drug classifications. For hypertension, it includes antihypertensives, diuretics, beta blocking agents, calcium channel blockers, and agents acting on the renin-angiotensin system. For diabetes, it includes insulin and analogues, blood glucose lowering drugs excluding insulins, biguanides, sulfonylureas, combinations of oral blood glucose lowering drugs, alpha glucosidase inhibitors, thiazolidinediones, DPP-4 inhibitors, GLP-1 analogues, SGLT2 inhibitors, and other blood glucose lowering drugs. The published entries also include lipid modifying agents for high cholesterol.
Who is affected
RMC No. 62-2020 directly affects VAT-registered pharmacies, drugstores, hospitals, clinics, wholesale distributors, medicine importers, healthcare companies, health maintenance organizations, employers reimbursing employee medicines, and accounting teams that validate input VAT, official receipts, invoices, and medicine purchases. CFOs and corporate accountants should pay particular attention where medicine purchases form part of employee health programs, hospital operations, pharmacy sales, reimbursement claims, or inventory accounting.
Consumers and patients are also affected because VAT exemption should reduce the tax burden on qualifying prescription drugs and medicines. However, the business compliance responsibility falls on sellers and other parties issuing invoices, receipts, and accounting records. The practical search terms for this issuance are VAT-exempt medicines Philippines, diabetes medicines VAT exemption, hypertension drugs VAT exempt, high cholesterol medicines VAT exempt, and RMC 62-2020 prescription drugs.
Key compliance rule: match the exact generic name, strength, and dosage form
The most important compliance requirement under RMC No. 62-2020 is exact matching. The list does not merely name broad product families. It identifies the generic name, dosage strength, and dosage form. For example, under diabetes medicines, the list includes metformin in 500 mg, 750 mg, 850 mg, and 1000 mg preparations, with forms such as tablet, film-coated tablet, extended-release tablet, sustained-release capsule, and oral solution. It also includes insulin products such as human insulin at 100 IU/mL, insulin aspart at 100 Units/mL, insulin degludec at 100 Units/mL, insulin glargine at 100 Units/mL and 300 Units/mL, and insulin glulisine at 3.49 mg/mL equivalent to 100 units/mL.
For hypertension, the list includes examples such as methyldopa 125 mg and 250 mg tablets, clonidine 75 mcg and 150 mcg tablets, hydralazine 25 mg and 50 mg tablets and 20 mg/mL solution for injection, hydrochlorothiazide 12.5 mg, 25 mg, and 50 mg tablets, furosemide 20 mg and 40 mg tablets and 10 mg/mL solution for injection, amlodipine 2.5 mg, 5 mg, and 10 mg preparations, losartan 25 mg, 50 mg, and 100 mg preparations, valsartan 40 mg, 80 mg, 160 mg, and 320 mg preparations, and telmisartan 20 mg, 40 mg, and 80 mg preparations. Combination medicines are also listed where the exact combination and strength appear, such as losartan plus hydrochlorothiazide and amlodipine plus valsartan plus hydrochlorothiazide in specified strengths.
For high cholesterol, the list includes lipid modifying agents, including statins and related preparations. The document also includes an addendum identifying medicines for inclusion and medicines for exclusion, which businesses should treat as especially important for inventory and pricing updates.
Effective date and deadline
The VAT exemption applies beginning January 27, 2020. Businesses should therefore review sales, purchases, inventory records, price tags, point-of-sale systems, accounting codes, and invoicing rules for covered prescription drugs from that date. For taxable periods affected by the January 27, 2020 start date, accounting teams should verify whether VAT was correctly excluded for qualifying medicines and whether VAT was correctly imposed on medicines not appearing in the list.
The issuance does not create a separate filing deadline in the published list. The immediate action item is classification and implementation: confirm which products are covered, update systems, and make sure receipts and invoices reflect the correct VAT treatment.
Addendum: medicines for inclusion and exclusion
The addendum is important because it shows that the VAT-exempt list is not static. Medicines added for inclusion include dulaglutide 1.5 mg/0.5 mL and 0.75 mg/0.5 mL solution for injection; insulin glargine and lixisenatide at 100 units per 33 mcg per mL and 100 units per 50 mcg per mL solution for injection; carvedilol 25 mg tablet or film-coated tablet; diltiazem hydrochloride 30 mg, 60 mg, 90 mg, 120 mg, and 180 mg preparations; losartan potassium plus hydrochlorothiazide plus amlodipine besilate in 100 mg/12.5 mg/10 mg and 50 mg/12.5 mg/5 mg film-coated tablets; levamlodipine besylate 2.5 mg and 5 mg tablets; terazosin hydrochloride 1 mg, 2 mg, and 5 mg tablets; teneligliptin hydrobromide hydrate 20 mg film-coated tablet; and linagliptin 5 mg tablet.
The addendum also identifies medicines for exclusion from the list. Excluded entries include sitagliptin as phosphate plus simvastatin in 100 mg plus 10 mg, 100 mg plus 20 mg, and 100 mg plus 40 mg film-coated tablets; metoprolol tartrate plus ivabradine hydrochloride in 25 mg plus 5 mg, 25 mg plus 7.5 mg, 50 mg plus 5 mg, and 50 mg plus 7.5 mg film-coated tablets; insulin degludec plus liraglutide 100 Units/3.6 mg per mL solution for injection; sacubitril plus valsartan 50 mg, 100 mg, and 200 mg film-coated tablets; bosentan 125 mg tablet or film-coated tablet; ambrisentan 5 mg and 10 mg film-coated tablets; and macitentan 10 mg film-coated tablet.
Penalties for non-compliance
RMC No. 62-2020 does not state a separate special penalty for misclassifying the listed medicines. However, the practical tax risk remains significant. If a seller treats a non-covered medicine as VAT-exempt, it may underdeclare output VAT. If a seller imposes VAT on a covered medicine, it may create pricing, customer refund, invoicing, and tax reporting issues. Incorrect classification may also affect VAT returns, books of accounts, inventory reports, and internal audit findings.
Because the list is specific, businesses should avoid generic assumptions. The defensible position is to retain product-level documentation showing the generic name, dosage strength, dosage form, and the basis for VAT-exempt treatment.
Practical steps for businesses now
First, create a product matrix matching each medicine SKU against the RMC No. 62-2020 list by generic name, dosage strength, and dosage form. Brand names alone are not enough. Second, flag products in the addendum as included or excluded so that the finance, pharmacy, purchasing, and point-of-sale teams apply the correct treatment. Third, update accounting codes so that VAT-exempt sales are not mixed with ordinary VATable sales. Fourth, train staff handling invoices, official receipts, inventory receiving, and reimbursement claims to check the exact medicine entry before applying VAT exemption. Fifth, periodically review FDA and BIR updates because the addendum shows that the list can be modified.
For hospitals, pharmacies, and medicine distributors, the most urgent review should focus on high-volume medicines such as metformin, insulin products, amlodipine, losartan, valsartan, telmisartan, atorvastatin, and common combination drugs. These are the types of products most likely to create repeated invoicing errors if the VAT classification is wrong at the system level.
ASG Law can assist with BIR compliance for VAT-exempt medicines
Ablola, Saribong & Gueco assists pharmacies, healthcare businesses, distributors, corporate taxpayers, and accounting teams in reviewing VAT classifications, BIR compliance exposure, invoicing practices, and documentation for tax audits. RMC No. 62-2020 is a product-level compliance issuance, and businesses should not rely on broad disease categories or informal supplier classifications. For assistance in reviewing VAT-exempt medicine classifications, tax compliance controls, or BIR audit risks, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.